Unauthorized Drugs Seized from Vancouver Gym
Health Canada enforcement officers have seized unauthorized pharmaceutical drugs from a Vancouver fitness facility. Discover the details of the raid and the ongoing risks of unregulated substances.
Category : Search result: pharmaceutical stocks
U.S. Approves Pill Version of Popular Weight-Loss Drug
U.S. regulators have greenlit a pill version of a leading weight-loss medication, potentially broadening treatment options. Learn about the approval and its implications.
FDA Approves Wegovy Weight Loss Pill
U.S. regulators have approved the Wegovy pill for weight loss, a major development in pharmaceutical treatment. Learn about the details and potential impact of this new drug.
TSX Transportation Stock Up 17%, Analysts Bullish
NFI Group shares surged 17% this week. Analysts from CIBC and others see further upside, citing a $13.2B order backlog. Plus, Desjardins' 2026 top picks and food inflation winners.
Fox Host Debunks Trump's 600% Drug Price Cut Claim
A Fox News anchor delivered a brutal math lesson on air, highlighting the impossibility of Trump's claim about slashing prescription drug prices by 600%. See the reality vs. perception clash unfold.
AI Concerns Hit Tech Stocks, Canadian Markets Mixed
Wall Street tech stocks fell on AI sector worries, leading to a mixed day for Canadian shares. The S&P/TSX composite was pulled lower by financial stocks. Get the full market analysis.
Health Canada Approves Drug for Rare Disease
Health Canada has granted approval for a new pharmaceutical treatment targeting a rare disease, offering hope for patients. Learn about the regulatory decision and its impact.
Pfizer 2026 profit forecast below expectations
Pfizer projects 2026 profits below Wall Street estimates due to a steep drop in COVID product sales and loss of exclusivity for key drugs. Get the full business analysis.
Wall Street Sees Double-Digit Stock Gains in 2026
Major Wall Street banks predict the S&P 500 will rise roughly 10% in 2026, driven by Trump tax cuts and rate cuts, despite AI bubble concerns. Get the full analysis.
Citigroup Sets 2026 STOXX 600 Target at 640
Citigroup forecasts the STOXX 600 index will reach 640 by the end of 2026, citing supportive fiscal policies as a key driver. Get the full analysis and market implications.
TSX up 300 points on strong bank results, tech gains
Canada's S&P/TSX composite surged nearly 300 points, fueled by robust financial sector earnings and technology stock advances. Get the full market analysis.
U.S. Stocks Steady Near Records on Mixed Earnings
U.S. equity markets hover near all-time highs as a wave of corporate profit reports delivers mixed signals. Key indices hold steady, reflecting investor caution and optimism.
BlackRock: AI to Dominate Markets in 2026 Despite Risks
Investment giant BlackRock forecasts artificial intelligence will continue driving markets in 2026, but warns of significant risks. Get the full analysis.
TSX dips while U.S. stocks rise on steady yields, bitcoin rebound
The S&P/TSX composite fell in a 'natural pause' as U.S. markets climbed, driven by stable bond yields and a bitcoin recovery. Get the latest on Canadian market movements.
China's Biopharma Surge Challenges Global Drug Leaders
China's biopharma industry is accelerating, fueled by record investment and streamlined supply chains. With faster development times and massive deals like AstraZeneca's $5.2B pact, the global drug innovation race is heating up. Discover the shift from ou
Asian Markets Mixed, TSX Dips After Wall Street Pullback
Global markets showed a split performance on December 2, 2025, with Asian shares ending mixed following a retreat on Wall Street. The S&P/TSX composite fell, pressured by bank losses. Get the latest market analysis.
Invest Now: The Case for Quality Stocks in 2025
Amid AI-fueled market bubbles, a rare opportunity emerges in undervalued quality stocks. Financial Times analysis reveals why this is a generational buying moment for Canadian investors.
Eli Lilly cuts price of obesity drug Zepbound
Pharmaceutical giant Eli Lilly has reduced the price of its obesity medication Zepbound to improve patient access. The move comes amid growing demand for GLP-1 drugs in Canada and globally.
TD's Top TSX Picks: Dollarama & Cybersecurity Stocks
Canadian investors eye Dollarama as cornerstone holding while AI cybersecurity risks create new opportunities. TD reveals top TSX stock picks for 2026 with analysis.
U.S. Stocks Rise on Last November Trading Day
U.S. stocks closed November with strong gains as investors showed renewed confidence. Key market indicators surged in the final trading session of the month.
Boehringer Ingelheim Names New Board Member for IT
Boehringer Ingelheim announces Harsha Deshmukh's appointment to Board of Managing Directors for IT and Global Business Services effective February 2026.
Uneven Economy Drives Black Friday Stock Picking
Canadian investors face complex Black Friday decisions as economic uncertainty reshapes retail stock strategies. Discover which sectors may outperform this shopping season.
Grey Bruce drug disposal nets meds for hockey tickets
Grey Bruce residents exchanged unused pharmaceuticals for Barrie Colts hockey tickets in a successful medication safety initiative. Learn how this program helps combat opioid misuse and environmental contamination.
Dipharma's Novel Method Detects Nitrosamine Risks
Dipharma publishes a peer-reviewed study unveiling a novel method to detect and characterize nitrosamine impurities in Active Pharmaceutical Ingredients, enhancing drug safety and regulatory compliance.
TSX gains led by energy, tech, and telecom sectors
Canada's main stock index climbed in late-morning trading, powered by strong performances in the energy, technology, and telecommunications sectors. Key business developments across multiple industries.
Canada's Fish Populations Could Recover Within Decade
New report shows Canada can restore healthy fish populations within a decade. Learn how sustainable fisheries management could transform Atlantic Canada's marine ecosystems.
Canadian Biotech Fights Stock Spoofing Claims
A Canadian biotechnology company faces allegations of stock manipulation as it fights to prove itself a victim of market spoofing. Learn about this financial battle.
Couche-Tard surges after earnings beat, CEO signals deals
Alimentation Couche-Tard shares surged nearly 5% after reporting better-than-expected earnings and CEO Alex Miller confirming active acquisition search across North America and Europe.
AI Bubble Bust Could Trigger 30% Market Plunge
Capital Economics warns an AI bubble burst could cause S&P 500 to drop 30% and tech sectors 60%, though the rally may continue through 2026 before correction.
TSX jumps 300+ points with tech sector leading gains
Canada's main stock index surged more than 300 points Monday as technology stocks rallied. The S&P/TSX composite posted strong gains amid positive market sentiment.
Page 1 of 4